Senate advances drug labeling bill after stripping key transparency safeguards

The Clear Labels Act, a bipartisan proposal by Senators Rick Scott and Kirsten Gillibrand to boost transparency in generic drug manufacturing, is poised for a full Senate vote after the Senate Health Committee stripped two core elements. The bill originally mandated that labels include a unique FDA facility identifier and required compliance within a year; both provisions have been removed, with the identifier eliminated and the timeline extended to five years.

Lawmakers argued the original requirements could raise drug prices and pose national-security risks, but safety experts and former FDA inspector Peter Baker contend the revisions dilute the bill’s intent. Without the identifier, linking drugs to specific overseas factories—such as those in India—becomes difficult, reducing the utility of tools like a journalist at one outlet. Industry lobbyists, including the Association for Accessible Medicines, have long resisted the initial requirements, claiming high costs for limited return. The revised legislation now only requires factory addresses, which can be vague, and the Senate is expected to consider it soon.